Hyperphosphatemia
Conditions
Brief summary
Hyperphosphatemia is highly prevalent in PD patients, and it is an independent risk factor for all-cause and cardiovascular mortality in these patients. Effective treatments are limited in suppressing plasma phosphorous. Because of the nearly linear relationship between protein and phosphorus intake, high dietary protein intake (DPI, 1.2-1.3g/kg/d recommended by KDOQI) would load high phosphorus burden in PD patients. It is suggested that hyperphosphatemia is hard to avoid under such a DPI level, even as the patients take sufficient phosphorus blinders and receive high PD dosage. The present study is to investigate whether systemic dietary instruction would show effects on control of hyperphosphatemia in PD patients.
Interventions
OTHERsystemic dietary instruction
systemic dietary instruction based on continuous quality improvement (CQI) team-oriented approach
Sponsors
Baxter Healthcare Corporation
Shanghai Jiao Tong University School of Medicine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Stable on PD for at least three month 2. Aged from 18 to 75 years old 3. Informed consent approval
Exclusion criteria
1. Malnutrition (based on SGA results) 2. Infection or inflammation within 1 month 3. Concurrent wasting disease (i.e. cancer, tuberculosis)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma phosphorus levels | up to 1 year |
Secondary
| Measure | Time frame |
|---|---|
| Plasma albumin levels | up to 1 year |
| Plasma calcium levels | up to one year |
| Carotid artery intima-media thicknesses | up to 1 year |
Countries
China
Contacts
Primary ContactNa Jiang, MD
Outcome results
None listed